Press Releases

12 April 2012	WILEX publishes financial report for the first quarter of 2012
11 April 2012	WILEX starts first patient study with MEK inhibitor WX-554
28 February 2012	WILEX reports on a successful financial year 2011
27 February 2012	FDA approves protocol amendment needed to conduct the final analysis of the pivotal RENCAREX^® Phase III trial
15 February 2012	WILEX Inc. appoints Walter Carney as CSO for the further development of Oncogene Science diagnostics
06 February 2012	WILEX receives funding from the German Federal Ministry of Education and Research for the development of WX-037 as part of the “m4 cluster initiative”
18 January 2012	WILEX successfully completed Phase I study in Healthy Volunteers with the oral MEK inhibitor WX-554

Press Archive

Seite gelesen: 3847 | Heute: 31